SpiD3 treatment encouraged translocation of CALR from the ER lumen to the cell surface membrane in both HG-3 and OSU-CLL cells within 24 h of treatment, in a manner comparable to the known CALR-translocating and ICD-inducing agent, etoposide. Here, CALR is linked to B-cell chronic lymphocytic leukemia.